Objective Drug plans take different approaches to determining reimbursement prices for
generic drugs. One common approach is to set the maximum reimbursement price as a …

Canadian drug plan pricing of generic drugs is in a state of flux, with different plans adopting
different approaches. The manner in which public plans pay for generic drugs can affect five …

During patent litigation, pay-for-delay deals involve a payment from a patent holder of a
branded drug to a generic drug manufacturer to delay entry and withdraw the patent …

During patent litigation, pay‐for‐delay (P4D) deals involve a payment from a patent holder of
a branded drug to a generic drug manufacturer to delay entry and withdraw the patent …

Many of the studies OHE Consulting performs are proprietary and the results are not
released publicly. Studies of interest to a wide audience, however, may be made available …

Following lengthy negotiations with the European Union (EU), Canada enacted Bill C-30 to
implement the LComprehensive Economic and Trade AgreementL in 2016 [1]. A particularly …

Full article: A Special Commemorative Issue Honoring William S. Comanor and 50 Years of
Pharmaceutical Economics Skip to Main Content Taylor and Francis Online homepage Taylor …

This thesis focused on investigating how the current commercialization landscape and,
specifically, the regulatory landscape, affects the market entry of biosimilars. A biosimilar is a …